Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia

Annals of Pharmacotherapy

Volumn 40, Issue 12, 2006, Pages 2200-2204

  Buie, Larry W ^a,b   Oertel, Maryann D ^a,b   Cala, Suzanne O ^a,b  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Allopurinol; Schizophrenia

Indexed keywords

ADENOSINE; ALLOPURINOL; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PLACEBO; PURINE RECEPTOR; XANTHINE OXIDASE; XANTHINE OXIDASE INHIBITOR;

ADJUVANT THERAPY; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERSENSITIVITY; MACULOPAPULAR RASH; MEDICAL LITERATURE; MEDLINE; PATHOGENESIS; PATHOPHYSIOLOGY; POSITIVE SYNDROME; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SCHIZOPHRENIA; TREATMENT DURATION;

ADJUVANTS, PHARMACEUTIC; ALLOPURINOL; ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33845604043     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H222     Document Type: Review

References (18)

1. Freedman R. Schizophrenia. N Engl J Med 2003;349:1738-49.
2. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004;363:2063-72.
3. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, 2nd ed. www.psych.org/psych_pract/treatg/ pg/Practice%20Guidelines8904/Schizophrenia_2e.pdf (accessed 2006 Feb 4).
4. Ferre S. Adenosine-dopamine interactions in the ventral striatum: implications for the treatment of schizophrenia. Psychopharmacology 1997; 133:107-20.
5. Lara DR, Souza DO. Schizophrenia: a purinergic hypothesis. Med Hypotheses 2000;54:157-66.
6. Lara DR, Dall'Igna OP, Ghisolfi ES, Brunstein MG. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:617-29.
7. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003;160:1209-22.
8. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004;27:596-601.
9. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-23.
10. Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q 2000; 71:373-84.
11. Stahl SM, Grady MM. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 2004;11:313-27.
12. Machado-Vieira R, Lara DR, Souza DO, Kapczinski F. Therapeutic efficacy of allopurinol in mania associated with hyperuricemia. J Clin Psychopharmacol 2001;21:621-2.
13. Lara DR, Cruz MR, Xavier F, Souza DO, Moriguchi EH. Allopurinol for the treatment of aggressive behavior in patients with dementia. Int Clin Psychopharmacol 2003;18:53-5.
14. Brunstein MG, Ghisolfi ES, Ramos FL, Lara DR. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J Clin Psychiatry 2005;66:213-9.
15. Lara DR, Brunstein MG, Ghisolfi ES, Lobato MI, Belmonte-de-Abreu P, Souza DO. Allopurinol augmentation for poorly responsive schizophrenia. Int Clin Psychopharmacol 2001;16:235-7.
16. Akhondzadeh S, Safarcherati A, Homayoun A. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double-blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:253-9.
17. Diagnostic and statistical manual for mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
18. Allopurinol. In: McEvoy GK, ed. AHFS drug information 2006. Bethesda, MD: American Society of Health-System Pharmacists, 2006:3603-7.